Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study

被引：0
|
作者：
Samuel, L.
Miller, R.
Ross, P.
Arkenau, T. [1 ]
Antony, G. [2 ]
Veneris, J.
Rule, J. [2 ]
Starling, N. [3 ]
机构：
[1] Sarah Cannon Res Inst, London, England
[2] GlaxoSmithKline, London, England
[3] Royal Marsden, London, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
芬兰科学院;
关键词：
D O I：
10.1016/j.annonc.2023.04.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-164
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [41] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
    Andre, Thierry
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Morse, Michael
    McDermott, Raymond S.
    Hill, Andrew Graham
    Hendlisz, Alain
    Lenz, Heinz-Josef
    Leach, Joseph W.
    Moss, Rebecca Anne
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Chan, Emily
    Kopetz, Scott
    Michael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study
    Guo, Weijian
    Bi, Feng
    Dong, Jian
    Jin, Chuan
    Niu, Zuoxing
    Wang, Yusheng
    Sun, Meili
    Wang, Teng
    Yu, Dajun
    He, Yifu
    Zhang, Ruixing
    Yin, Xianli
    Feng, Wenlei
    Zhang, Meijiang
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
    Andre, Thierry
    Berton, Dominique
    Curigliano, Giuseppe
    Ellard, Susan
    Trigo Perez, Jose Manuel
    Arkenau, Hendrik-Tobias
    Abdeddaim, Cyril
    Moreno, Victor
    Guo, Wei
    Im, Ellie
    Starling, Naureen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [44] Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
    Li, J.
    Xu, Y.
    Zang, A.
    Gao, Y.
    Gao, Q.
    Zhang, Y.
    Wang, D.
    Xu, J.
    Yuan, Y.
    Jiang, H.
    Ying, J.
    Shi, C.
    Deng, Y.
    Wang, J.
    Liu, T.
    Huang, Y.
    Shi, M.
    Wang, K.
    Hu, H.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S640 - S640
  • [45] MyTACTIC: Afficacy and safety of atezolizumab (atezo) plus chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR)
    Spigel, David R.
    Hussein, Maen A.
    Zuniga, Richard
    Mahadevan, Daruka
    Winn, Robert
    Darbonne, Walter C.
    Yoo, Bongin
    Kim, Young
    Whitehead, Zach
    Vanderwalde, Ari M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [47] Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
    Liao, Ying
    Zhu, Changhua
    Song, Xiaoxia
    Ruan, Jiugen
    Ding, Yao
    Chen, Yuan
    Yang, Qiujuan
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [48] Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC)
    Salem, M.
    Kopetz, S.
    El-Refai, S.
    Tabernero, J.
    Sinicrope, F.
    Tie, J.
    George, T.
    Van Cutsem, E.
    Mauer, E.
    Lonardi, S.
    Andre, T.
    Overman, M.
    Foureau, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S378 - S378
  • [49] Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.
    Huang, Jing
    Song, Yan
    Luo, Suxia
    Yin, Xianli
    Li, Enxiao
    Wang, Hui
    He, Yifu
    Liu, Zhihui
    Fan, Qingxia
    Liang, Xinjun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Nong
    Zhang, Shu
    Zhuang, Zhixiang
    Zhang, Jingdong
    Kou, Xiaoge
    Wang, Fen
    Zhu, Xiaodong
    Li, Shengmian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Molecular and immune landscape by cyclin dependent kinase (CDK) 4/6 expression and TP53 mutational status in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
    Wong, Alexandra
    Gandhi, Nishant
    Xiu, Joanne
    Algaze, Sandra
    Jayachandran, Priya
    Ashouri, Karam
    Soni, Shivani
    Zhang, Wu
    Lo, Jae Ho
    Mittal, Pooja
    Torres-Gonzalez, Lesly
    Weinberg, Benjamin Adam
    Lou, Emil
    Goel, Sanjay
    Yu, Jian
    Zhang, Lin
    Battaglin, Francesca
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 190 - 190
12345